MHRA launches adrenaline auto-injector safety campaign

MHRA launches adrenaline auto-injector safety campaign

  • 20 September 2023
  • News

Working with Anaphylaxis UK, MHRA has launched an adrenaline auto-injector (AAI) safety campaign to highlight the importance and safe use of AAIs as the emergency treatment of anaphylaxis.

AAIs are used as the first line treatment in a serious allergic reaction (known as anaphylaxis). As anaphylaxis can occur within seconds, an AAI must be administered as soon as anaphylaxis is suspected so it is important for those who are prescribed adrenaline to carry two in-date AAIs at all times. The second dose can be given after five minutes if there has been no improvement or symptoms are getting worse.

The development of the campaign first began in October 2019, when the Commission on Human Medicines (CHM) endorsed the formation of an AAI expert working group – which Anaphylaxis UK is part of – to examine how to support the effective use of AAIs. One of the agreed actions was to improve communications and develop a campaign to inform patients, healthcare professionals and the wider public.

The campaign features a step-by-step guide of what to do in an emergency including correct positioning, and what to do if you have been prescribed an AAI.

For more information, visit the AAI Safety Campaign (GOV.UK).